Measuring Dependence Severity Of Ketum

(Mitragyna Speciosa) Use Among Ketum Leaf Users

In Malysia by Singh, Darshan Singh  Mahinder
 
 
 
 
MEASURING DEPENDENCE SEVERITY OF KETUM 
(MITRAGYNA SPECIOSA) USE AMONG KETUM LEAF USERS 
IN MALYSIA 
 
 
 
 
 
by 
 
 
 
 
 
DARSHAN SINGH A/L MAHINDER SINGH 
 
 
 
 
 
 
 
 
 
 
 
Thesis submitted in fulfilment of the requirements  
for the degree of 
Doctor of Philosophy 
 
 
 
 
 
 
April 2013 
ii 
 
ACKNOWLEDGEMENT 
I would like to express my appreciation and gratitude to my 
principal supervisor Associate Professor Dr.B.Vicknasingam Kasinather, 
for all his indispensible support and valuable guidance during my study 
at the Centre for Drug Research, Universiti Sains Malaysia. I am also 
grateful to my co-supervisor the Director of Centre for Drug Research 
Professor Sharif Mahsufi Mansor, for all his excellent guidance and 
moral support.  
I would also thank Mr. Firdaus Bin Ramli from the Centre for 
Drug Research, for dedicating his precious time in helping me with my 
data collection. My special thanks to Miss Vemala Devi from the Centre 
for Drug Research, who obsequiously helped to edit my thesis. I also 
extent my sincere appreciation to Professor Suresh Narayanan from the 
School of Social Sciences, for guiding me in my statistical analysis 
work. I would also like to thank the Ministry of Sains and Technology 
(MOSTI) for financially supporting my research work. Last but not least, 
I thank Almighty for blessing me to excel in my studies. Finally I want 
to also thank both my loving parents the Late Mr. Mahinder Singh and 
Madam Jagjit Kaur who always encouraged me to do well in all my 
endeavours.   
iii 
 
 
TABLES OF CONTENTS 
Acknowledgement...........................................................................................  ii 
Table of Contents.............................................................................................  iii 
List of Tables...................................................................................................  xiii 
List of Figures..................................................................................................  xv 
List of Abbreviation.........................................................................................  xvii 
Abstrak.............................................................................................................  xx 
Abstract............................................................................................................  xxii 
                                                                                                                           
CHAPTER 1 - INTRODUCTION 
1.0 Introduction...............................................................................................  1 
1.1 Global Drug Abuse Situation....................................................................  1 
1.2 The Drug Abuse Problem in Malaysia......................................................  4 
1.3 Ketum (Mitragyna speciosa, Korth)..........................................................  10 
1.4 Ketum Studies in Humans.........................................................................  12 
1.5 Statement of Problem.................................................................................  14 
1.6 Research Questions.................................................................................... 16 
1.7 Study Objectives........................................................................................  16 
1.8 Scope of Study...........................................................................................  17 
1.9 Significance of Study.................................................................................  17 
1.10 Study Limitation......................................................................................  17 
1.11 Conclusion...............................................................................................  19 
iv 
 
CHAPTER 2 - LITERATURE REVIEW 
2.0 Introduction.............................................................................................  21 
2.1 History of Mitragyna speciosa or ‘ketum’ usage....................................  21 
2.2 Pharmacological Studies on M.speciosa.................................................  24 
2.3 Ketum Use in Humans............................................................................ 31 
       2.3.1 Ketum Dependence in Human......................................................  31 
       2.3.2 Ketum Withdrawal in Human.......................................................  32 
       2.3.3 Ketum Craving in Human.............................................................  35 
2.4 Law on Ketum Use in Malaysia..............................................................   35 
2.5 Types of Illegal Drugs and its Effects on Human...................................  36 
       2.5.1 Opiate............................................................................................  36 
       2.5.2 Cocaine..........................................................................................  38 
       2.5.3 Methamphetamine.........................................................................  39 
       2.5.4 Cannabis........................................................................................  41 
       2.5.5 Amphetamine................................................................................  43 
       2.5.6 Ketamine.......................................................................................  44 
       2.5.7 Codeine.........................................................................................  46 
       2.5.8 Benzodiazepine.............................................................................  46 
       2.5.9 Ecstasy..........................................................................................  48 
2.6 Early Addiction Theories........................................................................  49 
2.7 Drug Addiction and Diagnosis of Drug Dependence.............................  50 
       2.7.1 Stages of Addiction.......................................................................  52 
      
v 
 
       2.7.2 Diagnostic and Statistical Manual of Mental  
                Disorders-4th Edition.....................................................................  53 
2.8 Withdrawal Theories...............................................................................  55 
       2.8.1 Corticotropin-releasing factor (CRF)............................................  56 
       2.8.2 Reinstatement................................................................................  58 
       2.8.3 Cognitive-Behavioural Model.......................................................  59 
       2.8.4 Person-Situation Interaction Theory.............................................  60 
       2.8.5 Cognitive Appraisal Theory..........................................................  60 
       2.8.6 Self-Efficacy and Outcome Expectations......................................  61 
2.9 Craving Theories.....................................................................................  62 
       2.9.1 Craving and Loss of Control.........................................................  63 
       2.9.2 Urges and Craving.........................................................................  63 
       2.9.3 Theories of Craving-Conditioning Based Models.........................  64 
       2.9.3.1 Withdrawal Model......................................................................  65 
       2.9.3.2 Compensatory Response Model.................................................  66 
       2.9.3.3 Opponent-Process Model...........................................................  67 
       2.9.3.4 Incentive Conditioning Model....................................................  68 
       2.9.4 Allostasis and Neuroadaptation.....................................................  68 
       2.9.5 Activation of Behaviour................................................................  70 
       2.9.5.1 Dopamine and the Ventral Tegmental Area (VTA)...................  71 
       2.9.5.2 Amygdala...................................................................................  72 
       2.9.5.3 Prefrontal Cortex........................................................................  72 
       2.9.5.4 Nucleus Accumbens...................................................................  73 
vi 
 
       2.9.6 Incentive-Sensitisation Model........................................................  73 
       2.9.7 Unified Framework for Addiction Model......................................  75 
       2.9.8 Model of Interoceptive Dysregulation............................................  77 
       2.9.9 Pavlovian (or classical) Conditioning............................................  80 
       2.9.10 Prime Theory................................................................................  82 
       2.9.11 Motivation: Positive and Negative Reinforcement Mechanisms.   84 
2.10 Drug Substitution Treatment..................................................................  85 
       2.10.1 Methadone....................................................................................  86 
       2.10.2 Opioid Antagonists.......................................................................  88 
       2.10.3 Opioid Agonists............................................................................  89 
       2.10.4 Buprenorphine..............................................................................  90 
2.11 Detoxification.........................................................................................  91 
       2.11.1 Post-Withdrawal Interventions.....................................................  92 
2.12 Social Functioning..................................................................................  93 
2.13 Study Instruments...................................................................................  94  
       2.13.1 ASI................................................................................................  98 
       2.13.2 Leeds Dependence Questionnaire (LDQ)....................................   100 
       2.13.3 Marijuana Craving Questionnaire-Short Form (MCQ-SF).........   102 
       2.13.4 Marijuana Withdrawal Checklist (MWC)....................................  103 
2.14 Conclusion..............................................................................................  104 
 
 
 
vii 
 
CHAPTER 3 - METHODOLOGY    
3.0 Introduction..............................................................................................  105 
3.1 Study Location and Population................................................................  105   
3.2 Research Design......................................................................................  107 
3.3 Sampling and Data Collection.................................................................  107 
3.4 Study Incentive........................................................................................  110 
3.5 Sample Size.............................................................................................  110 
3.6 Study Respondents..................................................................................  111 
3.7 Study Inclusion Criteria...........................................................................  111 
3.8 Study Exclusion Criteria.........................................................................  112 
3.9 Urine Test................................................................................................  112 
3.10 Research Instruments............................................................................  113 
       3.10.1 Addiction Severity Index Fifth Edition.......................................   113 
       3.10.2 Leeds Dependence Questionnaire (LDQ)...................................   116 
       3.10.3 Marijuana Withdrawal Checklist (MWC)...................................  118 
       3.10.4 Marijuana Craving Questionnaire-Short Form (MCQ-SF)........   119 
3.11 Scoring...................................................................................................   120 
       3.11.1 Leeds Dependence Questionnaires..............................................   120 
       3.11.2 Marijuana Withdrawal Checklist................................................   120 
       3.11.3 Marijuana Craving Questionnaire-Short Form...........................  121 
       3.11.4 Addiction Severity Index.............................................................   121 
3.12 Training of Interviewer...........................................................................   121 
3.13 Translation Procedure............................................................................   122 
viii 
 
3.14 Measures Adopted to Minimize Acquiescence Biasness.......................  123 
3.15 Pilot Test................................................................................................  123 
3.16 Data Analysis.........................................................................................   124 
3.17 Chromatographic Analysis....................................................................  125 
3.18 Ethical Approval....................................................................................  126 
3.19 Conclusion.............................................................................................  127 
 
CHAPTER 4 - RESULTS 
4.0 Introduction..............................................................................................  128 
4.1 Sample Size..............................................................................................  128 
4.2 Respondent’s Sociodemographic Characteristics....................................  128 
       4.2.1 Gender and Age.............................................................................  129 
       4.2.2 Ethnicity.........................................................................................  129 
       4.2.3 Marital status..................................................................................  129 
       4.2.4 Employment..................................................................................  129 
       4.2.5 Occupation.....................................................................................  130 
       4.2.6 Education.......................................................................................   130 
       4.2.7 Accommodation.............................................................................  130 
       4.4.8 Income...........................................................................................  130 
       4.2.9 Family use......................................................................................  131 
       4.2.10 Sociodemographic Characteristics of Medium and Long-Term  
                   Ketum Users................................................................................  133 
       4.2.11 Summary of Respondent’s Sociodemographic Characteristics.  134 
ix 
 
4.3 Ketum Use History...................................................................................  134 
       4.3.1 Methods of Use..............................................................................  134 
       4.3.2 Former-Drug Users........................................................................  134 
       4.3.3 Duration of Ketum Use..................................................................  135 
       4.3.4 Age of First Ketum Use.................................................................  135 
       4.3.5 Daily Frequency of Ketum Use.....................................................  136 
       4.3.6 Daily Quantity of Ketum Use........................................................  136 
       4.3.7 Reasons for Using Ketum..............................................................  137 
4.4 Family Views and Cessation Effects.......................................................  138 
       4.4.1 Family Use.....................................................................................  138 
       4.4.2 Sexual Performance.......................................................................  139 
       4.4.3 Need to Use Ketum Daily..............................................................  140 
       4.4.4 Appetite..........................................................................................  140 
       4.4.5 Social Functioning.........................................................................  140 
       4.4.6 Ketum Addiction............................................................................  140 
       4.4.7 Sleeping Problems..........................................................................  141 
       4.4.8 Nervousness...................................................................................  141 
       4.4.9 Desire.............................................................................................  142 
       4.4.10 Treatment for Ketum Use Problems............................................  142 
       4.4.11 Days Suffered from Withdrawal..................................................  142 
       4.4.12 Abstinence History.......................................................................  143 
4.5 Ketum Dependence..................................................................................  144 
       4.5.1 Severity of Ketum Dependence.....................................................  144                              
x 
 
       4.5.2 Variables Associated with Severe Dependence............................  145 
       4.5.3 Variables Associated with Dependence Severity..........................  149 
4.6 Ketum Withdrawal..................................................................................  151 
       4.6.1 Physical Withdrawal Symptoms....................................................  153 
       4.6.2 Common Physical Withdrawal Symptoms....................................  155 
       4.6.3 Psychological Withdrawal Symptoms...........................................  156  
       4.6.4 Common Psychological Withdrawal Symptoms...........................  158 
       4.6.5 Withdrawal Severity in Medium and Long-Term Ketum Users..   159 
       4.6.6 Variables Associated with Severe Withdrawal.............................  160 
       4.6.7 Variables Associated with Ketum Withdrawal.............................  163 
       4.6.8 Common Physical Symptoms with Withdrawal Severity.............  165 
       4.6.9 Common Psychological Symptoms Associated  
                with Withdrawal Severity..............................................................  167 
4.7 Ketum Craving........................................................................................   170 
       4.7.1 Craving Intensity with other Variables..........................................   174 
       4.7.2 Variables Associated with High Craving for Ketum.....................   176 
4.8 Addiction Severity Index (ASI-5th Edition).............................................  177 
       4.8.1 Medical Problem...........................................................................  177 
       4.8.2 Employment Problem....................................................................  179 
       4.8.3 Alcohol/Drug Problem...................................................................  181 
       4.8.4 Legal Problem................................................................................  182 
       4.8.5 Family/Social Problem..................................................................  183  
       4.8.6 Psychiatric Problem.......................................................................   184 
xi 
 
       4.8.7 Composite Scores..........................................................................   186 
4.9 Conclusion................................................................................................  187 
       4.9.1 Socio-Demographic Characteristics...............................................  187 
       4.9.2 Ketum Use History.........................................................................  187 
       4.9.3 Ketum Dependence Severity..........................................................  188 
       4.9.4 Ketum Withdrawal Severity...........................................................  188 
       4.9.5 Ketum Craving...............................................................................  189 
       4.9.6 Addiction Severity Index...............................................................  189 
 
CHAPTER 5 - DISCUSSION 
5.0 Introduction..............................................................................................   190 
5.1 Sociodemographic Characteristics of Study Respondents......................   191   
5.2 Respondents Ketum Use History.............................................................   195 
5.3 Ketum Dependence..................................................................................   197 
5.4 Ketum Withdrawal...................................................................................  205 
5.5 Ketum Craving.........................................................................................  215 
5.6 Social Functioning...................................................................................   220 
       5.6.1 Medical Status................................................................................   223 
       5.6.2 Employment Status........................................................................  224 
       5.6.3 Alcohol and Drug Status................................................................  225 
       5.6.4 Legal Status....................................................................................   226 
       5.6.5 Family/Social Relationship Status.................................................  226 
       5.6.6 Psychiatric Status...........................................................................   227 
xii 
 
5.7 Conclusion...............................................................................................   228 
 
CHAPTER 6 - CONCLUSION  
6.0 Introduction.............................................................................................   230 
6.1 Summary of Results.................................................................................  230 
6.2 Study Implication....................................................................................   232 
6.3 Study Limitation......................................................................................   233 
6.4 Suggestions for Future Studies................................................................   234 
6.5 Conclusion...............................................................................................   234 
 
REFERENCES..............................................................................................   235 
APPENDICES 
 
 
 
 
 
 
 
 
 
 
xiii 
 
LIST OF TABLES 
                                                                                                 Page 
Table 2.1        Measurement Tools                                                 95 
Table 2.2        Leeds Dependence Questionnaire                          101 
Table 3.1        Study Locations                                                       106 
Table 3.2        Study Instruments                                                    113 
Table 3.3        Internal Consistency, Test-retest and Interclass                  125 
                       Correlation Coefficient Reliability Scores               
Table 3.4        Mitragynine Content                                               127 
Table 4.1        Demographic Characteristics of (n=293)                            132 
                       Respondents                                                            
Table 4.2        Sociodemographic Characteristics of Medium                   133 
                       and Long-term Users                                               
Table 4.3        Duration of Ketum Use                                           135 
Table 4.4        Dependence Severity of Medium and Long-term               145 
                       Ketum Users                                                             
Table 4.5        Variables Associated with Severe Dependence      148 
Table 4.6        Variables Associated with Dependence Severity    149 
Table 4.7        Physical and Psychological Withdrawal                             152 
                       Symptoms                                                                 
Table 4.8        Medium and Long-term Ketum Users                                159 
                       Withdrawal Severity                                                
Table 4.9        Variables Associated with Severe Withdrawal       160 
 
xiv 
 
Table 4.10      Factors Associated with Ketum Withdrawal                      163 
                       Severity                                                                     
Table 4.11      Common Physical Symptoms with Withdrawal                 165 
                       Severity                                                                    
Table 4.12      Common Psychological Symptoms with                            167 
                       Withdrawal Severity                                                 
Table 4.13      Intensity of Ketum Craving                                     170 
Table 4.14      Medium and Long-term Users Ketum                                172 
                       Craving Intensity                                                      
Table 4.15      Craving Intensity with Other Variables                  173 
Table 4.16      Variables Associated with High Ketum Craving     176 
Table 4.17      Composite Scores for (n=293) Ketum Users           186 
Table 5.1        A Comparison of the Sociodemographic                             194 
                       Characteristics between Four Other Studies            
Table 5.2        A Comparison between the Withdrawal                              212 
                       Effects of Four Other Studies                                   
 
 
 
 
 
 
 
 
 
xv 
 
LIST OF FIGURES 
                                                                                                                Page                                         
Figure 1.0       Annual Prevalence and Number of Illicit Drug        2 
                       Users at the Global Level, In the Late 1990s-2009/2010 
Figure 1.1       HIV Cases by Risk Factors                                       7 
 
Figure 1.2       Ketum (Mitragyna speciosa)                                    10 
Figure 2.1       Mitragyna speciosa Trees                                        21 
Figure 2.2       Chemical Structures of Mitragynine and  25 
                        7-Hydroxymitragynine 
Figure 3.1       A Sketch of the Targeted Study Areas                    109 
Figure 4.1       Daily Frequency of Ketum Use                               136 
Figure 4.2       Daily Quantity of Ketum Use                                  136 
Figure 4.3       Reasons for Ketum Use                                           137 
Figure 4.4       Family Views                                                           138 
Figure 4.5       Sleeping Problems                                                    141 
Figure 4.6       Days Suffered from Ketum Withdrawals                 142 
Figure 4.7       Ketum Dependence Severity                                    145 
Figure 4.8       Physical Withdrawal Symptoms                              154 
Figure 4.9       Seven Common Physical Withdrawal Symptoms   155 
Figure 4.10     Psychological Withdrawal Symptoms                     157 
Figure 4.11     Psychological Withdrawal Severity Symptoms       158 
Figure 4.12     Ketum Withdrawal Severity                                     159 
Figure 4.13     Ketum Craving                                          172 
Figure 4.14     Lifetime Hospital Admission                                   177 
xvi 
 
Figure 4.15     Medical Problems in the Last 30-days                     178 
Figure 4.16     Interviewer Severity Rating                                     179 
Figure 4.17     Work Patterns in the Last Three Years                    179 
Figure 4.18     Employment Problems                                             180 
Figure 4.19     Last Abstained from Ketum Use                              181 
Figure 4.20     Duration of Abstinence from Ketum Use               181 
Figure 4.21     Detained by Police                                                   182 
Figure 4.22     Involvement in Criminal Activity                            182 
Figure 4.23     Spending Time with Family and Friends                 184 
Figure 4.24     Reported Psychiatric Problems in the Last 30-Days          185 
Figure 5.1       Reasons for Using Ketum                                        196 
 
 
 
 
 
 
 
 
 
 
 
 
xvii 
 
LIST OF ABBREVIATIONS 
 
AADK                 Agensi Anti Dadah Kebangsaan 
ACTH                  Adrenocorticotropic Hormone 
AIDS                   Acquired Immunodeficiency Syndrome 
ALT                     Alanine Aminotransferase 
APA                    American Psychiatric Association 
ASI                      Addiction Severity Index 
AST                     Aspartate Aminotransferase 
ATS                     Amphetamine Type Stimulants 
BNST                  Bed Nucleus of Stria Terminalis 
BUP                    Buprenorphine  
BZ                       Benzodiazepine 
C&C                    Care and Cure 
CeA                     Central Nucleus of the Amygdala 
CNS                     Central Nervous System 
CR                       Conditioned Response 
CRF                     Corticotropin Releasing Factor 
CS                        Conditioned Stimuli 
DA                       Dopamine 
DSM-IV              Diagnostic and Statistical Manual of Mental Disorders 
HCT                    Hematocrit 
HCV                    Hepatitis C Virus 
xviii 
 
HGB                    Hemoglobin 
HIV                     Human Immunodeficiency Virus 
HPA                    Hypothalamic Pituitary Adrenal 
ICD-10                International Classification of Diseases 
IDUs                   Injecting Drug Users 
IM                       Interim Methadone 
LAAM                Levo-Alpha Acetyl Methadol 
LDQ                    Leeds Dependence Questionnaire 
MCHC                Mean Corpuscular Hemoglobin Concentration 
MCQ-SF             Marijuana Craving Questionnaire Short Form 
MDMA                3, 4-methylenedioxy-N-methylamphetamine 
METH/MA         Methamphetamine  
MMT                   Methadone Maintenance Treatment 
mRNA                 Messenger Ribonucleic Acid 
MS                       Mitragyna Speciosa 
MSM                   Male Who Have Sex with Males 
MWC                  Marijuana Withdrawal Checklist 
NADA                 National Anti-Drug Agency 
NADI                  National Drug Information System 
NMDA                N-Methyl-D-aspartate 
NSAID                Non-Steroidal Anti-Inflammatory Drug 
NSEP                   Needle Syringe Exchange Program 
OST                     Opiate Substitution Treatment 
xix 
 
PUSPEN             Pusat Pemulihan Penagihan Narkotik 
RBC                    Red Blood Cells 
STI                      Sexually Transmitted Disease 
THC                    Tetrahydrocannabinol 
UN                      United Nations 
UNAIDS             United Nations Programme on HIV/AIDS 
UNGASS            United Nations General Assembly Special Sessions  
                            On HIV and AIDS 
 
UNODC              United Office on Drugs and Crime 
US                       Unconditioned Stimuli 
USA                    United States of America 
VTA                    Ventral Tegmental Area 
WBC                   White Blood Cells 
WHO                   World Health Organisation 
 
Definition of terminology 
Dependence Implies use which is more problematic, compulsive, and 
difficult to stop despite adverse consequences.  
Withdrawal Is a clinical syndrome of unpleasant, sometimes dangerous, 
signs and symptoms developing after a period of substance use 
ends. Efforts to relieve withdrawal symptoms may lead to 
further drug use.  
Craving The subjective desire for the effects of a drug. A strong desire 
or sense of compulsion to take the substance.  
 
 
xx 
 
MENGUKUR KETERUKAN PERGANTUNGAN TERHADAP KETUM 
(MITRAGYNA SPECIOSA) DI KALANGAN PENGGUNA DAUN KETUM 
 DI MALAYSIA 
 
ABSTRAK 
Ketum atau Mitragyna speciosa merupakan sejenis tumbuhan psikotropik semulajadi 
yang selalu digunakan untuk nilai perubatannya. Kajian mengenai penggunaan 
ketum masih terhad, oleh itu penyelidikan lanjutan diperlukan untuk mengkaji risiko 
kesan penggunaan jangka panjang dalam manusia. Tujuan kajian adalah untuk 
menentukan ciri-ciri sosiodemografi, mengukur tahap keterukan pergantungan 
ketum, keterukan penarikan ketum, tahap gian terhadap ketum dan menilai fungsi 
sosial pengguna daun ketum. Sejumlah 293 pengguna ketum telah ditinjau dari tiga 
negeri di utara semenanjung Malaysia (Pulau Pinang, Kedah dan Perlis). Kajian 
keratan rentas menggunakan teknik persampelan bukan-kebarangkalian (purposif dan 
kuota) telah digunakan untuk mengumpul data. Empat instrumen kajian iaitu Leeds 
Dependence Questionnaire, Marijuana Withdrawal Checklist, Marijuana Craving 
Questionnaire-Short Form, dan Addiction Severity Index telah digunakan untuk 
mengukur tahap keterukan pergantungan terhadap ketum dikalangan pengguna daun 
ketum. Semua peserta adalah lelaki, majoriti berbangsa Melayu. Lapan-puluh lima 
peratus mempunyai pekerjaan, 46% adalah di antara umur 18-25 tahun, 41% sudah 
berkahwin, manakala tiga-perlima telah menamatkan 11 tahun (SPM) pendidikan. 
Tujuh-puluh sembilan peratus melaporkan bahawa mereka perlu menggunakan 
ketum setiap hari, 83% melaporkan ketum boleh menyebabkan ketagihan jika 
digunakan dengan kerap, 64% mengalami masalah susah tidur, 67% menjadi 
gementar, 72% tidak dapat mengawal keinginan terhadap ketum dan 90% 
xxi 
 
mempunyai fungsi sosial yang baik. Tiada perbezaan yang signifikan diantara 
pengguna ketum jangka sederhana dan jangka panjang dari aspek keterukan 
pergantungan terhadap ketum (p>0.243), keterukan penarikan terhadap ketum 
(p>0.322) dan tahap gian terhadap ketum (p>0.777). Lima-puluh lima peratus 
daripada sampel menunjukkan pergantungan terhadap ketum yang teruk, 33% 
menunjukkan keterukan penarikan terhadap ketum dan didapati 23% menunjukkan 
kegianan yang tinggi terhadap ketum. Mereka yang minum ≥4 gelas ketum setiap 
hari (setiap gelas bersamaan dengan 350ml jus ketum segar) lebih cenderung 
melaporkan pergantungan terhadap ketum yang teruk (OR: 4.09; 95%CI: 2.32-7.24; 
p = 0.001), penarikan terhadap ketum yang teruk (OR: 3.31; 95%CI: 1.96-5.59; p = 
0.001) dan gian tinggi terhadap ketum (OR: 2.47; 95%CI: 1.41-4.34; p = 0.001). 
Tambahan pula, tiada kesan ketara dalam fungsi sosial pengguna ketum jangka 
sederhana dan jangka panjang. Tidak terdapat perbezaan ketara diantara pengguna 
ketum jangka sederhana dan jangka panjang dalam keterukan pergantungan terhadap 
ketum dan fungsi sosial. Lebih banyak kajian khasnya kajian klinikal diperlukan 
untuk menunjukkan keselamatan penggunaan ketum dalam manusia.  
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MEASURING DEPENDENCE SEVERITY OF KETUM (MITRAGYNA 
SPECIOSA) USE AMONG KETUM LEAF USERS  
IN MALAYSIA 
 
ABSTRACT 
Ketum or M.speciosa is an indigenous psychotropic plant commonly used for its 
medicinal value. Studies on ketum use is still scarce, hence further research is needed 
to elucidate its prolonged use risk in humans. Study aim to determine the 
sociodemographic characteristics, measure ketum dependence severity, ketum 
withdrawal severity, ketum craving intensity and analyze the social functioning of 
ketum leaf users. A total of 293 ketum users were surveyed from three northern 
states of peninsular Malaysia (Penang, Kedah and Perlis). A cross-sectional study 
design using non-probability sampling techniques (purposive and quota) was used to 
collect data. Four study instruments specifically the Leeds Dependence 
Questionnaire, Marijuana Withdrawal Checklist, Marijuana Craving Questionnaire-
Short Form, and Addiction Severity Index were used to measure ketum dependence 
severity among ketum leaf users. Respondents were all male, majority of Malay 
ethnicity. Eighty-five percent were employed, 46% were between the ages of 18-25 
years, 41% were married, while three-fifths had completed eleven years (SPM) of 
education. Seventy-nine percent reported that they need to use ketum daily, 83% 
reported ketum can cause addiction if used regularly, 64% encountered sleeping 
problems, 67% became nervous, 72% were unable to control ketum desire and 90% 
had better social-functioning. There were no significant differences between medium 
and long-term ketum users in their ketum dependence severity (p>0.243), ketum 
withdrawal severity (p>0.322), and ketum craving intensity (p>0.777). Fifty-five 
xxiii 
 
percent of the sample reported severe ketum dependence, 33% reported severe ketum 
withdrawal and 23% reported high ketum craving. Those who consumed ≥4 glasses 
of ketum daily (each glass is equivalent to 350ml of fresh ketum juice) were more 
likely to report severe ketum dependence (OR: 4.09; 95%CI: 2.32-7.24; p = 0.001), 
severe ketum withdrawal (OR: 3.31; 95%CI: 1.96-5.59; p = 0.001) and high ketum 
craving (OR: 2.47; 95CI%: 1.41-4.34; p = 0.001). In addition, there were no 
significant impairments in the social functioning of medium and long-term ketum 
users. There were no significant differences between medium and long-term ketum 
users in their ketum dependence severity and social functioning. More studies 
especially clinical studies are needed to show the safety of ketum use in human. 
 
1 
 
CHAPTER 1 
INTRODUCTION 
1.0 Introduction  
 This chapter introduces the topic of thesis. The global drug problem and 
widespread ketum use practice is discussed in this chapter. In addition, the research 
questions and study objectives are also clearly elucidated in this chapter.  
1.1 Global Drug Abuse Situation 
 The 1United Nations Office on Drugs and Crime (UNODC) estimated that a 
total of 149 to 272 million people (3.3% to 6.1% of the world population between the 
age of 15-64 years) around the world have used illicit substances in 2009/2010 
(UNODC, 2011). An additional 22 million people are estimated to have used illicit 
drugs in 2009/2010, compared to the previous year, as shown in Figure 1.0. The 
sharp increase in the number of illicit drug users globally, could be attributed to the 
widespread abuse of non-medical use of prescription drugs, and the uncontrolled 
availability of ‘legal highs’ (UNODC, 2011). On the contrary, the prevalence rate for 
problem drug use continued to remain stable from 2008 to 2010, despite a marginal 
increased in the global prevalence rate of illicit drug use (UNODC, 2011). UNODC 
estimated that there are approximately 15 to 39 million (0.9 to 3.3 of the world 
population between the age of 15-64 years) problem drug users worldwide, of which 
15.9 million are forecasted to be injecting drug users (Mathers et al., 2008). It is 
interesting to note that the use of new synthetic psychotropic substances such as 
                                                            
1 UNODC-United Nations Office on Drugs and Crime 
2 
 
‘legal highs’ (e.g. spice, krathom) is beginning to gain more prominence among 
substance users around the globe (UNODC, 2011; Vandrey et al., 2012).    
  
    Source: (UNODC, 2011).    
    Figure 1.0 Annual prevalence and number of illicit drug users at the global    
    level in the late 1990’s to 2009/2010.  
 
 Cannabis is the most widely used and produced illicit drug around the world. 
UNODC estimated that approximately 125 to 203 million people have used cannabis 
at least once in 2009. 2Amphetamine-type-stimulant (ATS) is the second most 
extensively used illicit drug globally. It is estimated that about 13.7 to 15.64 million 
people aged between 15-64 years have used ATS drugs at least once in 2009 
(UNODC, 2011). About 10,600 (26% increase compared to the previous year) ATS 
related clandestine manufacturing laboratories were eradicated in 2009 (UNODC, 
2011). The third most commonly used illicit drugs are opiates. UNODC estimated 
that approximately 12 to 21 million people have used opiates globally in 2009, of 
which three-quarters were heroin users.  
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 The global opium poppy cultivation area in 2010 has increased marginally 
(195,700 hectares) compared to 2009 (185,900 hectares), and nearly two-thirds of the 
world opium is produced in Afghanistan. However, the global opium yields reduced 
significantly in 2010, mainly due to disease in opium poppy plants in Afghanistan 
(UNODC, 2011). In 2009, seizure for ATS type of drugs have surged significantly, 
compared to 2007. However the seizure for heroin/morphine remained stable in the 
last three years. Demand for opiate treatment in countries like Europe and Asia 
remained high, while treatment demand for ATS use continued to escalate in 
countries like Southeast Asia, North America and West and Central Europe 
(UNODC, 2011).              
 People who use illicit drugs by injection route are irreversibly exposed to 
multiple health problems, such as 3Human Immunodeficiency Virus (HIV). At 
present, globally 33.4 million people are living with HIV, and HIV transmission is 
reported to be high in women (UNAIDS, 2010). Two million deaths are reported per 
year, while 2.7 million new infections are reported yearly. Only about 40% knew 
about their HIV status. About 4.7 million people in Asia are infected with HIV, and 
nearly 10 million people are still waiting to receive treatment for HIV. The reference 
group to the UN on HIV and Injecting Drug Use, estimated that there were 
approximately 15.9 million (range 11-21 million) injecting drug users worldwide, 
and in fact, roughly 3.0 million (range 0.8-6.6 million) people who injected drugs 
might be HIV positive. UNODC estimated that in 2009, one out of five injecting 
drug users are HIV positive. The three countries with the highest prevalence of HIV 
and number of injectors were reported in China (12%), USA (16%) and Russia 
(37%), respectively (Mathers et al., 2008). The reference group also estimated that in 
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2007, there were about 3.4 to 4.9 million people who injected drugs in East and 
Southeast Asia, of which 313,000 to 1.2 million people are HIV positive (Mathers et 
al., 2008).  
 Injecting with a contaminated needle and syringe used by someone infected 
with hepatitis C (HCV), has been identified as the primary risk factor for 4HCV 
transmission during a drug injecting episode (Garfein et al., 1998). The prevalence of 
hepatitis C among injecting drug users at the global level is estimated to be at 50%, 
of which nearly 8.0 million IDUs are infected with hepatitis C (UNODC, 2011). 
Overdose is a leading cause of death among illicit drug users (Degenhardt et al., 
2006). Of the 104,000 to 263,000 reported deaths per year are due to the use of illicit 
drugs, in fact, more than half of the mortality incidents are caused by overdose 
(UNODC, 2011). 
1.2 The Drug Abuse Problem in Malaysia    
 Malaysia has been experiencing a serious drug abuse problem since the 1970s, 
and the increase in HIV spread in Malaysia stems from the illegal abuse of drugs. 
Between 1988 and 2006 more than 300,000 individuals, approximately 1% of the 
general population were registered as substance abusers in Malaysia, with heroin 
abuse accounting for 62.6% of those registered in Malaysia (5AADK, 2007). In fact, 
the actual number of illicit drug users in the country could be larger than the reported 
figures. In 2012 the Reference Group to the United Nations on HIV and Injecting 
Drug Use, estimated that there are approximately between 170,000 to 240,000 
injecting drug users in Malaysia, and the prevalence rate of HIV among people who 
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inject drugs in the country was 10.3%, while about 22% of the 6IDUs are living with 
HIV (Mathers et al., 2008; UNGASS, 2010). Between 4,135 to 6,538 drug users, 
were reported to be receiving opiate substitution treatment (OST) in the country in 
2010 (Mathers et al., 2010).   
 2011 National Drug Report indicated that a total of 4,784 drug users are 
currently enrolled in 20 government drug rehabilitation centres nationwide (Pusat 
Pemulihan Penagihan Narkotik-PUSPEN), of which 126 are female drug users 
(AADK, 2011). At present, nearly 56,314 recovering drug users are enrolled in 
7Therapeutic Community (TC) program under the supervision of National Anti Drug 
Agency. Since the inception of Cure and Care programme (C&C), about 528 drug 
users have voluntarily sought treatment from C&C clinics until the end of December 
2011 (AADK, 2011).        
 The 2011 National Drug Report, reported that heroin (followed by ATS and 
cannabis) still remains the most popular and widely abused illicit drug in Malaysia 
(AADK, 2011). There has been a significant increase in the seizure for heroin base, 
heroin no.3, syabu, yaba pills, psychotropic pills and ketum juice in the country in 
2011, compared to 2010 (AADK, 2011). Relapse rate among drug users in Malaysia 
is high, and can sometimes reach up to 70-90% (Reid et al., 2007). The 2011 
National Drug Report also reported, that there have been a marked increase (17.99%) 
in the number of people arrested under the Dangerous Drug Act 1952 in 2011 
(111,719), compared to 2010 (94,689) (AADK, 2011). Hence, forty-percent of the 
Malaysian prison population who were incarcerated in 2007 were held for drug-
related offences (Amnesty International, 2011).         
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 Almost ten thousand (9,776) illicit drug users were detected in 2011, of which 
(63% were new, and 37% ex-drug users) in the country. Notably, the number of 
illicit drug users detected in 2011 (9,776) have decreased markedly, compared to 
2010 (23,642) (AADK, 2011). This significant decrease is primarily attributed to the 
establishment of the voluntary treatment based ‘Care & Cure’ clinics, scaling-up of 
8methadone maintenance treatment (MMT) programmes, and the constant police 
crackdowns on drug peddlers and tracffickers. The highest number of drug users in 
the country in 2011, were detected in Perak, Penang and Kuala Lumpur (AADK, 
2011). Majority of the drug users in Malaysia were still in their adolescent age (range 
19-34), in fact most had completed lower secondary education (nine years of 
education) (AADK, 2011).     
 The HIV transmission in Malaysia is predominantly driven by IDUs who are 
engaged in receptive drug injecting behaviours, as shown in Figure 1.1. Based on the 
2010 Malaysian AIDS council report, the national HIV incidence rate in 2010 was 
12.9 cases per 100,000 persons (Malaysian AIDS Council, 2010), and the prevalence 
of HIV infection among street drug users accessing 9Needle Syringe Exchange 
Programme (NSEP) in Malaysia, ranges from 25% to 45% (Kamarulzaman, 2009; 
Ministry of Health Malaysia, 2009). In fact, 73.7% of the reported HIV cases in 
Malaysia occurred among people who used drugs (Mesquita et al., 2008; UNGASS, 
2008). The first HIV case in Malaysia was reported in 1986, since than the HIV 
pandemic continued to proliferate, prompting the government to adopt pragmatic 
harm reduction measures to curtail HIV spread among the IDU population. As of 
December 2009, a total of 87,710 (79,691 males, 8,091 females) HIV cases have 
been reported throughout the national HIV surveillance system (UNGASS, 2010). 
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The HIV epidemic is found to be largely concentrated in four ‘most-at-risk’ 
population with a prevalence of (>5%). The four most-at-risk population include; 
IDUs, female sex workers, men having sex with men (MSM), and transgender 
(UNGASS, 2010). Kelantan, Pahang, Kuala Lumpur and Johor reported to have the 
highest HIV incidence rates in Malaysia (Malaysian AIDS Council, 2010).  
                     
                 
      Source: Malaysian AIDS Council 2010. 
       Figure 1.1 HIV Cases by Risk Factors. 
 
 
 A study conducted by Chawarski et al., (2006) among heroin dependents in 
Malaysia showed, HIV prevalence was significantly high among heroin users who 
reported lifetime drug injection history, lack of consistent condom use, and Malay 
ethnicity. This is true, since less than three-quarters (71.4%) of the HIV patients in 
Malaysia were Malays (Malaysian AIDS Council, 2010). 
 Similarly, in a recent local study conducted by Vicknasingam et al., (2008) 
showed that, IDUs preferred to inject drugs due to peer influence, decrease in heroin 
purity, shortage of heroin supply, and also to maximise euphoric effects. Nineteen 
IDUs in the study were injecting heroin with benzodiazepines. Findings from the 
study also showed, that IDUs frequently shared their injecting equipments (e.g. 
cookers, rinse water, syringes, etc), and reported injecting in groups. Among one of 
the earliest studies assessing the injection drug using behaviours of IDUs in Kelantan 
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in 1992, reported that out of the 210 recruited IDUs, 30% (62/210) were HIV 
positive, and half reported sharing other IDUs’ injecting paraphernalia during the last 
time of their injection (Singh and Crofts, 1992). Moreover, a study conducted by 
Vicknasingam et al., (2009) among out-of-treatment drug users reported, 65% of the 
study participants (n=522) were HCV positive, and the HCV incidence rate was high 
in IDUs than non injecting drug users.  
 In addition, study conducted by Bachireddy et al., (2011) among HIV-infected 
male prisoners in Malaysia found, out of the 102 participants, 66% reported sharing 
needles, and 37% had unprotected sex in the last 30-days prior to their incarceration. 
During their pre-incarceration period (30-days), 77% reported injecting drugs, while 
71% were injecting drugs daily. Findings from the study also showed, nearly 32% 
reported 1-10 episodes of sharing their needle or syringe, 13% reported 11-30 
episodes, and 41% reported 31 or more episodes of engaging in risky drug injecting 
behaviours. Hence, approximately half (51%) of the participants believed that 
10(OST) would be helpful, 54% believed that OST after release would prevent 
relapse, and 70% expressed interest in learning more about OST options.        
 In another study conducted by Vicknasingam et al., (2010) reported, 11BUP 
IDUs in Malaysia remained at high risk of HIV transmission because of continued 
injection drug use, and sharing of injection equipments. BUP injection drug use 
during the past 30-days was reported by 97%, and 63% reported at least daily BUP 
injection drug use during the past 30-days. Of the 480 participants, almost a third 
was (27%) reported to be HIV positive. Findings from the study also showed, 
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lifetime sharing needles was reported by 82% (n=225/276), and current sharing was 
reported by 55% (n=153/276) of the participants.      
 IDUs who inject ATS type of drugs are also susceptible to HIV infection. A 
study conducted by Chawarski et al., (2012) found, out-of-treatment opiate injectors 
who used ATS are at elevated risk of HIV infection in Malaysia. Findings from the 
study showed, of the 732 opiate IDUs, 27.6% (194/704) were HIV positive. Two 
factors were found to be significantly associated with HIV infection in this sample; 
lifetime history of ATS use, and lifetime history of sharing injection equipment. It 
appears that opiate IDUs in Malaysia are engaging in high risk behaviours regardless 
of their HIV status, and the transition into ATS injection drug use could be due to the 
low purity of street heroin in Malaysia (Vicknasingam and Navaratnam, 2008), and 
the widespread availability of ATS drugs.     
 Out of the 11,194 registered drug cases in 2011, about 76.72% were using 
drugs via chase route, 14.09% smoked, 4.58% took drugs orally, 4.51% injected, and 
0.10% drank drug solutions (AADK, 2011). Of the 11,194 drug users, 70.82% were 
abusing opiates, 14.82% ATS and 13.93% cannabis (AADK, 2011). Indeed, the 
seizure for processed ketum juices, and dried ketum leaves have increased 
substantially in the country. This reflects that ketum is probably used as a substitute 
for other illicit drugs, since findings from (Vicknasingam et al., 2010) showed ketum 
can be used as a narcotic substitute to reduce addiction to other drugs, as well as 
ameliorate opiate withdrawal symptoms. The 2011 National Drug Report showed, 
seizure for ketum have increased four-fold, compared to 2010 (22,790.92 liters). In 
2011, 85,058.35 liters of processed ketum juice, and 2,784.21 kg of dried ketum 
leaves were seized by the enforcement agencies (AADK, 2011). This significant 
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increase in ketum seizure indicates that ketum is fast gaining more popularity due to 
its psychotropic like effects.  
1.3 Ketum (Mitragyna speciosa, Korth) 
                         
 
                             Figure 1.2 Ketum Tree 
 
 Ketum or locally known as ‘biak’, and in Thailand as ‘krathom’ (Mitragyna 
speciosa, Korth) is an indigenous tropical plant of Southeast Asia, as shown in 
Figure 1.3. Ketum trees can be widely found in the northern states of Peninsular 
Malaysia, as well as, in the central and southern parts of Thailand. Village folks have 
used ketum leaves for decades traditionally for its medicinal value, and for its 
narcotic-like effects which resembles like coca and opioids (Shellard, 1989; Grewal, 
1932). Ketum leaves have been used in Malaysia as an opium substitute when opium 
itself was unavailable or unaffordable, and was also used to suppress opiate 
withdrawal symptoms (Burkill, 1935; Burkill and Haniff, 1930; Jansen and Prast, 
1988). According to (Kumarnsit et al., 2006) the leaves are the most effective part of 
the plant. Mitragynine is reported to be a central nervous system stimulant rather 
than a depressant. However its effects are ‘dose-dependent’ (Grewal, 1932a), it 
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induces stimulant effects at lower doses, and opiate effects at higher doses in humans 
(Babu et al., 2008). Wray (1907a) reported that krathom effects were similar to 
opium, with large doses leading to stupor, while a “slothful life” was a result of 
habitual use. Despite its narcotic-like effects, ketum leaves have been traditionally 
used by rural folks as a remedy to counteract fever, malaria, cough, hypertension, 
diarrhoea, to prolong sexual intercourse, and to treat opiate addiction 
(Assanangkornchai et al., 2007; Idayu et al., 2011). People in the northern states 
believed that ketum using practice is an intractable aspect of their socio-culture, and 
it is often used in the community during social gatherings.   
 Males commonly used krathom leaves to enhance their work productivity, 
while in Thailand the society does not accept female ketum addicts (Suwanlert, 
1975). Ketum leaves can be chewed, smoked or brewed into herbal tea. Ketum users 
in Thailand like to chew krathom leaves, whereas in Malaysia ketum is commonly 
ingested as a solution. Krathom leaves produce greater effect when chewed (Grewal, 
1932). Extracts from ketum leaves contain several active alkaloids. But the two 
alkaloids particularly, 12Mitragynine and 137-Hydroxymitragynine is reported to 
have exceptional opiate-like properties, although it’s chemical structure is quite 
different from that of morphine. Mitragynine is a major constituent which accounts 
for two-thirds of the total alkaloids extracted from the young ketum leaves (Shellard, 
1974). Mitragynine which is an opioid receptor agonist, exhibits antinociceptive 
actions in supraspinal opioid systems when orally administered in rodents 
(Matsumoto et al., 1996a), and its action is dominantly mediated by mu and delta 
receptors (Matsumoto et al., 1996a). 7-hydroxymitragynine which is another minor 
constituent of mitragyna speciosa (Ponglux et al., 1994) is a novel opioid agonist 
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(Matsumoto et al., 2005). This alkaloid is 13 times stronger than morphine, and 46 
times stronger than mitragynine (Takayama et al., 2002). 7-hydroxymitragynine is 
reported to induce potent analgesic activity when orally administered (Matsumoto et 
al., 2004). The mitragynine content in ketum leaves may vary, depending on the 
geographic origin of trees and seasons (Shellard et al., 1974). 
 The “Thai Narcotic Book” written by Norakanphadung in (1966) reported that 
krathom was weaker than morphine with shorter effects, less harmful than cocaine 
and had a milder withdrawal syndrome than was seen with opiates. It was said to 
stimulate like coca, and have a depressive effect like opium and cannabis. Krathom 
leaves have been used in Thailand, to treat morphine addicts. Preclinical trials in 
humans, carried out by Smith, Kline and French Laboratories in the 1970’s, 
apparently revealed that ketum can induce some unacceptable acute effects (Raffauf, 
1986). In a nutshell, it seems many Asians can tolerate krathom effects despite of its 
chronic administration (Jansen and Prast, 1988b). 
1.4 Ketum Studies in Human 
 To date, numerous animal studies have been carried out to determine the 
pharmacological efficacy of Mitragyna speciosa, korth. Studies on opiate receptor 
bindings, anti-inflammatory activity, analgesic potency, neurogenic contraction of 
vas deferens, and anti-depressant efficacy of Mitragyna speciosa have shown to be of 
significant value. Similarly, toxicity and cognitive behavioural function studies 
conducted in animal models showed, Mitragyna speciosa can induce severe 
hepatotoxicity, mild nephrotoxicity, physical dependence and cognitive impairments 
when administered in high doses.  
13 
 
Previous studies on ketum use in humans were exploratory and descriptive in 
nature. In fact, they chiefly elucidated the demographic characteristics of ketum 
users, patterns of use, duration of use, and the prolonged withdrawal effects of ketum 
use (Suwanlert, 1975; Assanangkornchai et al., 2007; Vicknasingam et al., 2010; 
Ahmad and Aziz, 2012). Krathom was generally used in Thailand by middle age 
labourers, mainly to heighten their physical tolerance to hard work under the blazing 
sun, and to combat fatigue (Suwanlert, 1975). Suwanlert (1975) reported that 
krathom users eventually become dependent on krathom after using krathom for 
prolonged periods. Likewise, findings from a more recent study showed people in 
Thailand commonly used krathom to improve work efficiency, and to relieve fatigue 
(Assanangkornchai et al., 2007). People in Thailand often viewed krathom using 
practice as less harmful, than other illicit drugs. Hence, about 61% of the regular 
krathom users in Assanangkornchai et al., (2007) study, reported being dependent on 
krathom. Nevertheless, krathom was also reported to be used in Thailand in the past 
to treat morphine addicts (Suwanlert, 1975), and its use as an opiate suppressor was 
also mentioned by Jansen and Prast (1988a). In a more recent study conducted by 
(Vicknasingam et al., 2010) showed, ketum is getting more appeal among poly-drug 
users particularly in the northern states of Malaysia, where it is used to help reduce 
addiction to other illicit drugs, and to attenuate opiate withdrawal effects. 
Ketum is also reported to be used in Europe and in United States as “legal 
highs”. Ketum or Krathom can be easily acquired via some internet sites without 
doctor’s prescription (Schmidt et al., 2011). Findings from a recent study showed, a 
43-year old man in the United States who suffered from chronic pain reported to 
have used krathom to relieve opioid withdrawal, and to self-manage his chronic pain 
(Boyer et al., 2008). In another case from Germany, a 25-year old man was 
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diagnosed with “intrahepatic cholestasis” (i.e. a medical condition caused by 
interruption in the excretion of bile-a digestive fluid that helps the body process fat) 
after ingesting powdered krathom for two weeks (Kapp et al., 2011). While a 64-year 
old patient from United States was also rushed into an emergency room after he was 
found at home unconscious, and in seizures after using krathom tea (Nelsen et al., 
2010). Another internet based survey conducted with representatives from 13 
different countries, found a small proportion of the respondents in the United States 
(42 out of the 50 states) preferred to use miscellaneous drugs such as krathom with 
spice probably to augment euphoric effects (e.g. synthetic cannabinoids) (Vandrey et 
al., 2012).          
 Apart from drinking unadulterated ketum juice, there are more alarming issues 
concerning the increasing abuse of the 144x100 cocktail in Thailand (Tanguay, 2011). 
The 4x100 cocktail is usually concocted with krathom, cough syrup/benzodiazepines, 
coca-cola and chilled with ice cubes. This adulterated concoction can lead to serious 
addiction problems. In fact, many ketum users in the northern states of peninsular 
Malaysia have begin to use the 4x100 ketum cocktail for a better high.   
1.5 Statement of Problem      
Ketum leaves have been used since decades for its innocuous medicinal 
properties, despite its reported narcotic effects. At present, there is a paucity of 
research on whether prolonged ketum use can lead to severe dependence, 
withdrawal, cause craving, and impair the social functioning of ketum users. The 
National Drug Information System (NADI) does not capture any epidemiological or 
behavioural information on ketum users. The only available source of information on 
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ketum in the country is on ketum seizures, which is documented in the National Drug 
Report. According to the National Drug Report, seizure for ketum has increased 
markedly in the last few years. In 2011, 83,466.12 litres of processed ketum juice 
and 1,626.65/kg of dried ketum leaves were confiscated (AADK, 2011). The seizure 
for both processed ketum juice and dried ketum leaves increased significantly in 
2009 (5,139.61 litres/ 1,797.85 kg) and in 2010 (6,484.36 litres/ 1,637.55 kg) 
(AADK, 2008-2011). Nevertheless, more ketum users are diverting into anomalous 
ketum using practices, like mixing ketum with other illicit substances. Concocted use 
of ketum juice can cause ketum users to develop severe ketum dependence and 
withdrawal problems, and cause other adverse health problems to ketum users.  
 
 Suwanlert (1975), Assanangkornchai et al., (2007) and Vicknasingam et al., 
(2010) reported, that prolonged ketum use can cause dependence, and abrupt 
cessation from ketum use can lead to adverse withdrawal effects. Ahmad and Aziz, 
(2012) reported, 87% of respondents in their study, were unable to refrain from 
ketum use when they wanted. Similarly, nearly 78% of the respondents in 
(Vicknasingam et al., 2010) study reported that they were unable to quit from ketum 
use.  
 Previous studies on ketum use in humans were generally descriptive and 
exploratory. No objective measures were used to measure and assess the severity of 
ketum dependence, withdrawal, craving intensity, and the social functioning of 
ketum users. Studies conducted in Thailand and Malaysia only provided the context 
of ketum use among human subjects. The self-report of dependence and withdrawal 
were captured qualitatively. More quantitative studies are needed to show whether 
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prolonged ketum use can adversely lead to severe ketum dependence problem, and 
impair the social functioning of ketum users.   
1.6 Research Questions  
Based on the statement of problem, five research questions are posed in this study.  
a) What are the sociodemographic characteristics of ketum users in Malaysia? 
b) What is the severity of ketum dependence among ketum users in Malaysia? 
c) What is the severity of ketum withdrawal among ketum users in Malaysia? 
d) What is the intensity of ketum craving among ketum users in Malaysia? 
e) What are the social domains where ketum users’ social functioning is 
affected?    
 
1.7 Study Objectives 
Five study objectives were constructed for this study, as listed below: 
a) To determine the sociodemographic characteristics of ketum users in 
Malaysia. 
b) To measure the severity of ketum dependence among ketum users in 
Malaysia. 
c) To measure the severity of ketum withdrawal among ketum users in 
Malaysia.  
d) To measure the intensity of ketum craving among ketum users in Malaysia.   
e) To analyze the social functioning (e.g. medical, employment, legal, 
family/social relationship, and psychiatric status) of ketum users in Malaysia.  
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1.8 Scope of Study 
 Information gathered through focus group discussions with several key 
informants, literature review and fieldwork observations showed that ketum is now 
gaining more widespread appeal among the local populace in the northern states of 
Peninsular Malaysia. Ketum use in these states (Penang, Kedah and Perlis) are 
rampant, thus these locations were selected for this study.     
 
1.9 Significance of Study 
 To my knowledge, this study is first to provide some vital insights on the 
effects of ketum use in humans, especially in Malaysia. At this juncture, it is still 
unknown whether prolonged ketum use can lead to severe ketum addiction problems. 
In fact, future studies can rely on the findings of this study to build their 
investigations more methodologically. The instruments used in this study were 
adapted, and may be used as a diagnostic tool by general practitioners for measuring 
ketum dependence, withdrawal, craving and the social functioning of ketum users 
seeking treatment in clinical settings. Findings from this study can also fill some of 
the gaps in ketum literature, specifically in human subjects.   
 
1.10 Study Limitation 
 This study has some limitations, thus results from this study should be 
interpreted with caution. First, the sample was non-randomly selected, and on that 
account our results cannot be generalized to all ketum users in the northern states or 
elsewhere, since the study was a cross-sectional survey study mainly designed to 
determine severity of ketum dependence in regular ketum users. It was not possible 
to use a probability sampling technique, because ketum users were scattered in small 
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numbers across the study locations, as well as, there was no sampling frame available 
for ketum users. The size of ketum population is still yet to be determined in 
Malaysia. Both purposive and chain referral sampling techniques were used to recruit 
respondents for this study. Traditionally, non-random sampling methods (e.g. chain 
referral and targeted sampling) have been used to sample hidden populations because 
sampling frames are unavailable for such populations (Watters & Biernacki, 1989). 
These proposed sampling methods are considered suitable because of its potential to 
generate a representative sample, and other advantages including, efficiency, cost 
effectiveness, increased safety for research staff, and has the potential to reach the 
most hidden segment of target populations (Johnston et al., 2008a).       
 
 Second, data in this study is based on self-reports, which may affect the 
validity of the findings, hence recall bias due to social desirability might also exist. 
In view of the retrospective nature of this study design, findings from this study 
might be subjected to inaccuracy, over-reporting or probably under-reporting. In 
order to overcome these limitations, all the interviews were carried out in places 
which were convenient for both the interviewer and interviewee. Respondents were 
assured that no ‘personal identifiers’ describing their whereabouts will be collected, 
and were also allowed to take their time in answering the questions.  
 
 Third, there was significant difficulty in recruiting ketum users for this study. 
Potential ketum users in some targeted study locations refused to cooperate with the 
researcher. Ketum users in these locations were unwilling to participate in the study, 
because they were afraid that their personal information would be disclosed to the 
police. Fourth, the researcher also encountered some difficulty in recruiting ketum 
19 
 
users who only used ketum. Many ketum users in some of the targeted study 
locations were using other illicit drugs, or were mixing their ketum drinks with other 
substances, thus making them unsuitable for the study. 
 
1.11 Conclusion  
 The next chapter is the literature review chapter. Detailed explanation 
regarding the pharmacological effects of ketum use in humans and animal models, 
types of illegal drugs and their effects, drug dependence, withdrawal theories, caving 
theories, treatment modalities, and the different types of measurement instruments 
are discussed in the following chapter. There are six chapters altogether in this thesis 
and the summary of each chapter is shown below. 
 
Chapter 1: In the first chapter, the global substance abuse problem, HIV prevalence 
in IDUs, the ketum and illicit drug abuse problem in Malaysia, problem statement, 
study objectives and study limitations are clearly elucidated.  
 
Chapter 2: The second chapter covers the literature review. In this chapter, all the 
relevant and important literature relating to the study context is delineated. 
 
Chapter 3: The third chapter is the methodology chapter. In this chapter, the type of 
study design, study instruments, inclusion and exclusion criteria, as well as the study 
locations and how the study was conducted are explained.  
 
Chapter 4: The fourth chapter is the results chapter. In this chapter, all the 
significant differences between the study participants are analyzed and presented. 
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Chapter 5: The fifth chapter is the discussion chapter which discusses the findings 
of the current study, and the findings are compared with previous studies.        
Chapter 6: The sixth chapter is the final chapter of the thesis. In this chapter all the 
findings are summarized. It also provides some recommendations on how to improve 
and conduct future studies related to ketum use in human subjects. This final chapter 
also addresses some of the current gaps in the existing studies on ketum use in 
humans. 
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CHAPTER 2 
LITERATURE REVIEW 
2.0 Introduction 
 In this chapter, various important literature on Mitragyna speciosa, 
pharmacological studies on M.speciosa, types of illicit drugs and their effects, the 
definition of drug dependence, withdrawal and craving, drug substitution treatment, 
detail description of study instruments used in this study, and recommended study 
tools for future studies are delineated and discussed. 
 
2.1 History of Mitragyna speciosa or ketum usage 
 
      
 Figure 2.1 Mitragyna speciosa Trees. 
 Mitragyna speciosa Korth, as shown in Figure 2.1, which belongs to the 
Rubiaceae family, is a tropical plant of Southeast Asia. Ketum trees can be found 
widely in the northern states of Peninsular Malaysia and southern Thailand. Ketum 
threes usually grow in hot and wet climate. This indigenous plant is popularly known 
in Malaysia as ‘ketum’ or ‘biak’, and in Thailand as ‘krathom’. Krathom leaves have 
been used since olden times both in Thailand and Malaysia for its ‘opium-like’ and 
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‘cocaine-like’ effects (Grewal, 1932; Burkill, 1935) for increasing work productivity 
(Suwanlert, 1975). Ketum was reported to be a central nervous system stimulant 
rather than a depressant (Grewal, 1932a). Ketum leaves have been used since the 
colonial era by the natives of Malaya as an “opium-substitute”, when opium supply 
was unavailable and unaffordable (Burkill, 1935). In Thailand krathom was used to 
wean morphine addicts off morphine addiction (Suwanlert, 1975). Moreover, 
krathom was reported to have the potential to suppress, as well as ameliorate opiate 
withdrawal symptoms (Burkill and Haniff, 1930; Vicknasingam et al., 2010).  
 Ridley in 1897 described that krathom leaves can be used as a cure for opium 
habit. After several decades Shellard (1974) claimed, that krathom does not have 
addictive properties like morphine, indeed it was weaker than morphine because it 
induces transient withdrawal effects, which is less harmful than cocaine 
(Norakanphadung, 1966). Krathom leaves were generally chewed to “calm the mind” 
(Suwanlert, 1975). Apparently many Asians are able to tolerate its effects, especially 
on daily basis (Jansen and Prast, 1988). The only disadvantage of ketum is, when it is 
used in large doses it induces stupor, while an indolent life is a result of frequent and 
prolonged indulgence in ketum use (Jansen and Prast, 1988). Those who get the habit 
of using it, find it as difficult to leave off ‘biak’ use (Burkill, 1935).       
 Besides using it for its narcotic-like effects, ketum leaves were also 
traditionally used for its medicinal properties. Rural folk normally used ketum leaves 
to treat various health problems, such as diabetes, hypertension, fever, diarrhea, 
muscle strain, prolonging sexual intercourse, as a wound poultice, and to alleviate 
fatigue (Suwanlert, 1975; Reanmongkol et al., 2007). Hence, manual workers usually 
chew krathom leaves to improve their work productivity, or to boost their physical 
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endurance under the blazing sun (Suwanlert, 1975; Assanangkornchai et al., 2007). 
Krathom leaves can be chewed, as well as brewed into tea. Krathom users in 
Thailand prefer to chew krathom leaves, while in Malaysia ketum is usually 
consumed as a herbal tea. The former practice is quite rare in Malaysia, compared to 
Thailand. There are two types of krathom leaves, red and green veined leaf. The red 
veined species is reported to have stronger pharmacological activity, than the latter 
(Chittrakarn et al., 2008). It is an offence to use ketum in Malaysia and Thailand. 
However, people from both this geographical divide still continue to adamantly use 
ketum, despite its prohibition. Regular krathom users in Thailand believe that their 
krathom using practice does not disturb anyone, and krathom is better than other 
illicit substances (Assanangkornchai et al., 2007). Ahmad and Aziz (2012) reported 
that 99% of the ketum users in their study have not neglected their families, despite 
being a regular ketum user.  
 During the old days krathom was popular among the older age people who 
mainly used krathom for its medicinal effects. In fact, many young people are 
beginning to use ketum now, probably for its stimulant and euphoric like effects. If 
used excessively krathom may cause ‘psychological dependence’ (Win Pe, 1980). 
However, krathom withdrawal syndrome was reported to be milder than opiates 
(Jansen and Prast, 1988). Currently, krathom can be purchased from several internet 
sites as “legal-highs” or as herbal dietary supplements, where information on its 
adverse side-effects is scantily disclosed (Schmidt et al., 2010). On the other hand, 
processed ketum juice can also be easily acquired from unscrupulous ketum traders 
in the community for local consumption. 
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2.2 Pharmacological Studies on M.speciosaan alkaloid, accounts for about 66% of         
          The pioneers’ researcher who worked with M. speciosa in 1897 was Ridley. In 
the early nineteen century, Wray (1907) described that krathom leaves can be 
smoked, chewed or consumed as an infusion with opium-like effects regardless of 
the method of administration. Since Field first isolated mitragynine in 1921, 
numerous investigations have been conducted to determine the pharmacological 
efficacy of M.speciosa use, specifically for its analgesic value. Up to now, over 25 
alkaloids have been isolated from the leaves of M.speciosa, in fact the two principal 
components which have received overwhelming research interest in the last couple of 
years include mitragynine (major alkaloid of MS1) and 7-hydroxymitragynine (a 
minor constituent of MS). These two compounds are reported to have potent 
analgesic effects. The chemical structures of both the compounds are depicted in 
Figure 2.1. The other analogues of M.speciosa encompass speciogynine, 
speciociliatine, and paynantheine (Takayama, 2004). Mitragynine is an indole 
alkaloid which accounts for about 66.2% of the total alkaloid extracted from the 
young leaves of M.speciosa (Ponglux et al., 1994; Shellard, 1974). Mitragynine is an 
opioid receptor agonist (Watanabe et al., 1992; Tsuchiya et al., 2002).  
 Mitragynine was reported to be a central nervous system stimulant rather than a 
depressant (Grewal, 1932a). However the effects of M.speciosa are dose-dependent, 
it induces stimulant effects at lower doses, and opiate effects at higher doses 
(Suwanlert, 1975, Grewal, 1932). Notably, large doses escalate exploratory 
behaviour without the opiate “fear and rage” complex in cat (Jansen and Prast, 1988). 
Kumarnsit et al., (2007) reported that M.speciosa extract has ‘stimulatory effect’ on 
                                                            
1 MS (Mitragyna speciosa). 
